Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

64Cu SAR bisPSMA - Clarity Pharmaceuticals

Next Previous
Search
Drug Profile

64Cu SAR bisPSMA - Clarity Pharmaceuticals

Alternative Names: 64Cu SAR bisPSMA; Cu-64 SAR-bisPSMA

Latest Information Update: 25 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clarity Pharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 19 Feb 2025 64Cu SAR bisPSMA receives the Fast Track Designation from the US FDA for the diagnosis of patients with biochemical recurrence (BCR) of prostate cancer following definitive therapy prior to February 2025
  • 19 Feb 2025 Clarity Pharmaceuticals initiates the phase III AMPLIFY trial in Prostate cancer (Diagnosis) in Australia
  • 28 Jan 2025 Efficacy data from phase-I/II COBRA trial in Prostate cancer released by Clarity Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top